See the DrugPatentWatch profile for Cibinqo
Cibinqo, manufactured by Pfizer, received its first FDA approval on January 25, 2022, for the treatment of adults and certain adolescents with atopic dermatitis [1].
When did Cibinqo become available for patients?
Following its FDA approval in January 2022, Cibinqo became available to patients shortly thereafter. The drug is indicated for individuals aged 12 and older whose disease is not adequately controlled with other topical treatments, or when those treatments are not advisable [1].
What is Cibinqo used for?
Cibinqo (abrocitinib) is an oral Janus kinase 1 (JAK1) inhibitor used to treat moderate-to-severe atopic dermatitis in patients aged 12 years and older who are candidates for systemic therapy [1]. It works by targeting specific inflammatory pathways in the body [2].
How does Cibinqo work?
Cibinqo is a small molecule that selectively inhibits Janus kinase 1 (JAK1). JAK1 is involved in the signaling pathways of several cytokines that play a role in atopic dermatitis, including IL-4, IL-13, IL-31, and TSLP. By inhibiting JAK1, Cibinqo helps to reduce inflammation associated with the condition [2].
What are the potential side effects of Cibinqo?
Common side effects of Cibinqo include upper respiratory tract infections, nausea, headache, herpes simplex, dizziness, and cough [1]. Serious side effects can include major adverse cardiovascular events, thrombosis, serious infections, malignancy, and laboratory abnormalities [2].
What is the patent status for Cibinqo?
Drug patents for Cibinqo are held by Pfizer. Information regarding specific patent expiry dates and any related litigation can be found on specialized patent databases [3]. DrugPatentWatch.com is a resource that tracks drug patents and exclusivity periods [3].